IMAP France advises BIOGROUP on the acquisition of CMA-Medina in Belgium

BIOGROUP has acquired CMA-Medina, the leading player in medical lab testing in Belgium.

This is BIOGROUP’s first acquisition abroad, and part of a strategy to become a leading European player through expansion into other countries, while continuing its development in France and Belgium. Following the transaction, BIOGROUP will be majority owned by Dr Stéphane Eimer and the De Raedt-Verheyden family (founder of CMA-Medina).

Currently majority-owned by Doctor Stéphane Eimer, BIOGROUP operates over 710 labs, located in Eastern France, Ile-de-France, Nouvelle-Aquitaine, Provence-Alpes-Côte d'Azur, Rhône-Alpes, Corsica and Western France. The Group is the leading player in medical lab testing in France with a pro-forma revenue of €930 million in 2019. Owned by Straco, the De Raedt-Verheyden family’s holding company, CMA-Medina is the leading player in medical lab testing in Belgium, with 8 laboratories and 25 sampling centers, mainly in Flanders.

Dr. Stéphane Eimer, Chairman of BIOGROUP declared: “The merger with CMA-Medina is a key step in the development of BIOGROUP and we are proud to now become a leading European player. I look forward to working with the CMA-Medina's team and Straco management to continue the successful development they have achieved in Belgium and now in Europe. The health crisis related to Covid-19 has enabled us to work together to optimize our mutual public health capabilities.”

IMAP France (Degroof Petercam) acted as financial advisor to BIOGROUP in this transaction and its financing. Degroof Petercam is the leading player in M&A and financing advisory in the medical lab testing industry, with 11 transactions completed since January 2020.

More news